drugset / Trial / NCT00002406

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

NCT00002406

Phase 3 Completed 350 enrolled Merck Sharp & Dohme LLC
Open-labelTreatment

Summary

The purpose of this study is to determine if two dose levels of indinavir combined with two nucleoside analogue reverse transcriptase inhibitors (NRTIs) have the same effect on plasma viral load (level of HIV in the blood).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject INDINAVIR ANHYDROUS Other / unclassified 800 mg
Subject INDINAVIR ANHYDROUS Other / unclassified 1200 mg